Learn how you can stall the development of full-blown Multiple Myeloma with evidence-based nutritional and supplementation therapies.
Click the orange button to the right to learn more.
According to the research linked below, approximately 25% of multiple myeloma are diagnosed with renal impairment. Further, kidney problems can result in both MGUS as well as SMM patients. In my experience working with both pre-MM as well as full MM patients, kidney damage can be more of a health challenge than the patient’s monoclonal proteins.
To complicate the life of the MGUS, SMM and MM patient further, bone health is another life long challenge. In other words the pre-mm, full mm patient/survivor must manage his/her kidney and bone health for their entire lives.
And there are conventional, FDA approved therapies that can improved both kidney and bone health.
But there are situations when the patient, for whatever reason, would prefer evidence-based but non-toxic therapies to manage his/her kidney damage. According to the first article linked below, “resveratrol treatment reduced blood urea nitrogen levels and creatinine levels by 20 and 24%…”
BUN, (blood urea nitrogen) and creatinine are a diagnostic tests that both pre-mm and full mm patients undergo frequently. These tests keep an eye on the patient’s kidney health.
Finally, while I’m talking about the life long health challenges of the pre and full mm patient/survivor, I have to point out that all patients will eventually reach multi-drug resistance aka MDR. MDR is an unpleasant fact of the mm survivor.
Please consider evidence-based but non-conventional, non-toxic, non-FDA approved therapies shown to enhance the efficacy of chemotherapy. According to the third study linked below, resveratrol enhances the efficacy of velcade/bortezomib.
The bottom line, as far as I can see, is that the MGUS, SMM and MM patient must look beyond conventional therapies when managing his/her blood disorder or blood cancer. Consider resveratrol.
To learn more about evidence-based but non-toxic therapies to manage your pre and full MM, scroll down the page, post a question or comment and I will reply to you ASAP.
“Inflammation plays an important role in polycystic kidney disease (PKD). The current study aimed to examine the efficacy of the anti-inflammatory compound resveratrol in PKD and to investigate its underlying mechanism of action…
“Background: Renal impairment (RI), a severe complication in multiple myeloma (MM), is considered as a poor prognostic factor… However, specific evolution of the incidence of RI in MM and its impact on prognosis remain unclear…
Results: In our population-based study, 24.6% of MM patients presented with RI (12.9% required haemodialysis). Median survival time was 21 months in patients with RI versus not reached at 3 years for other patients (P < 0.01). Age >73 years, RI, comorbidities and non-use of drugs or ASCT were associated with excess mortality risk.
The effect of RI on excess mortality rates was maximum in the first 6 months after diagnosis. In the observational study, median follow-up time was 22.5 months; factors associated with renal response were haematologic response [odds ratio (OR) 6.81; P < 0.01] and previous chronic kidney disease (OR 0.26; P = 0.04).
Factors associated with 1-year overall survival were haematological [hazard ratio (HR) 0.13; P < 0.01] and renal response (HR 0.27; P = 0.03).
Conclusions: RI represents an independent negative prognostic factor in MM in the first 6 months after diagnosis. Renal recovery and haematologic response are the strongest markers associated with patient survival.”
“Results: H929R was confirmed as a MM cell line that is resistant to BTZ. RSV enhanced the sensitivity of H929R cells against BTZ via inhibition of cell viability and colony formation, induction of cell apoptosis and regulation of expression of apoptosis-related proteins. Furthermore, RSV inhibited the expression of Hh signaling proteins (p < 0.05.
Conclusion: RSV enhances the sensitivity of MM cells to BTZ, partly via Hh signaling pathway. Thus, Hh pathway is a probable target for MM treatment, and RSV has potentials for use in the clinical management of MM.”
“In conclusion, low‐dose resveratrol supplementation significantly improved BMD of the lumbar spine and femoral neck and reduced the bone resorption marker, CTX, in postmenopausal women. The magnitude of benefit was greater for women with suboptimal bone metabolism. The resveratrol‐induced improvement in CVR and femoral neck T‐score suggests that improvement of the microcirculation may be an additional area to target in preventing postmenopausal osteoporosis.
Furthermore, the benefits of resveratrol on spine and hip BMD appeared to be amplified in women who regularly consume vitamin D and calcium supplements. Additional clinical randomized controlled trials are warranted to test whether this unique combination can improve the vascular and osseous profiles of the elderly women.